Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q
November 28, 2022 16:47 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing...
Vivos Therapeutics Provides Update on Revenue Recognition Review
November 22, 2022 07:30 ET
|
Vivos Therapeutics, Inc
Detailed Analysis Finds Minimal Impact on Prior Financial Results;No Previously Reported Revenue to be Lost Previously Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000;...
Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
August 26, 2022 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing...
Vivos Therapeutics Provides Update on Second Quarter Earnings Delay
August 22, 2022 16:05 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos”) is providing an update on the delay in announcing its second quarter 2022 financial results. ...
Vivos Therapeutics to Reschedule Second Quarter 2022 Financial Results Conference Call
August 15, 2022 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Schedules Second Quarter 2022 Financial Results Conference Call
August 09, 2022 08:00 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Announces Exclusive Distribution Agreement with GM Instruments, Ltd. for the U.S. and Canada
June 29, 2022 08:00 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., June 29, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-stage medical technology company focused on developing innovative...
Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea
June 14, 2022 08:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-generating medical technology company focused on developing...
Vivos Therapeutics to Present at Upcoming SLEEP 2022 Annual Meeting
May 26, 2022 08:00 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., May 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a medical technology company focused on developing and commercializing a...
Vivos Therapeutics Reports First Quarter 2022 Financial Results and Operational Update
May 16, 2022 16:05 ET
|
Vivos Therapeutics, Inc
First Quarter Appliance Revenue Increased 19% Year-Over-Year Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., May 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics,...